T he central roles of salt (NaCl) and the kidneys in the pathogenesis of most forms of hypertension are well established. 1, 2 The linkage between NaCl retention and blood pressure (BP) elevation is often referred to as "whole body autoregulation." 3, 4 Surprisingly, however, the precise mechanisms that underlie this linkage (ie, the signaling pathway) have escaped elucidation. Here, we examined the evidence that endogenous ouabain (EO), Na ϩ pumps (Na,K-ATPase), and the Na/Ca exchanger (NCX) are critical molecular mechanisms in this pathway.
Ca

2؉ and the Control of Myogenic Tone
At constant cardiac output (CO), mean arterial BPϭCOϫTPR (where TPR is total peripheral vascular resistance). 5 In most (chronic) hypertension, in humans and animals, the CO is relatively normal, and the high BP is maintained by an elevated TPR. 1, 4 TPR is controlled dynamically by vasoconstriction/dilation in small "resistance" arteries, which exhibit tonic constriction ("tone"). This can be studied in isolated, cannulated small arteries that develop spontaneous (myogenic) tone (MT), 6 under constant or increasing intraluminal pressure. Indeed, the level of tone in isolated arteries "is often comparable to that observed in the same vessels in vivo," 6 and may even be used to predict BP changes 7 (see below). MT is triggered by Ca 2ϩ entry, primarily through voltagegated Ca 2ϩ channels in arterial smooth muscle (SM; ASM) cells, 6 and contraction is activated by the rise in cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] CYT ). 8 In NaCl-dependent hypertension, the enhanced vasoconstriction and increased tone and TPR are, at least in part, functional and reversible phenomena. 9 Numerous mechanisms contribute to the regulation of myocyte [Ca 2ϩ ] CYT and vasoconstriction, but the plasma membrane (PM) NCX provides an unique, direct link between Na ϩ and [Ca 2ϩ ] CYT and, thus, Ca 2ϩ signaling and contraction in ASM cells. 10 NCX-mediated Ca 2ϩ transport is governed by the Na ϩ electrochemical gradient generated by the PM Na ϩ pump. We proposed that an endogenous Na ϩ pump inhibitor, ie, a ouabain-like compound, with vasotonic action might be secreted in response to NaCl retention. 11 In other words, this substance might be a missing hormonal link between NaCl retention and the increased TPR and hypertension. Conservation of the high-affinity ouabain binding site amino acid sequence in mammalian evolution (see below) implies that there must be an endogenous ligand for this site. Partial Na ϩ pump inhibition by the endogenous inhibitor should promote the net gain of Ca 2ϩ via the myocyte NCX and thereby augment Ca 2ϩ signaling and vasoconstriction. 10, 11 
Endogenous Ouabain
These ideas triggered an intense international search for the postulated endogenous Na ϩ pump inhibitor, a ligand for the ouabain/digoxin binding site of the pump, that might mediate the vascular response. In 1991, our group purified EO from human plasma; the substance was identified as ouabain by mass spectroscopy. 12 It is now possible to quantify EO by liquid chromatography-tandem mass spectroscopy starting from small (1-mL) samples of human or animal plasma. 13 The liquid chromatography-tandem mass spectroscopy spectra from human and rodent plasma extracts exhibit a major product ion at a mass:charge ratio of 445 ( Figure S1 to S3, available in the online data supplement at http://hyper.ahajournals.org); this is the lithiated aglycone of EO (ie, lithiated ouabagenin). The possibility that EO might be the 11␤ isomer of ouabain 14 is excluded, because the 11-epimers of ouabain have different chromatographic behavior. 15 Rat adrenal cortex is highly enriched with EO, and human and cow adrenals also contain very high levels. 12 Bilateral adrenalectomy causes a large decline in rat plasma EO, whereas treatment of uninephrectomized rats with deoxycorticosterone acetate (DOCA)ϩNaCl increases plasma EO Ͼ10-fold, and significantly elevates BP. 12 These data imply that EO is primarily an adrenocortical hormone, although it may also be synthesized in, and secreted by, the hypothalamus. 16 Studies of humans and intact animals, and of adrenocortical cell cultures, reveal that EO is synthesized in the adrenal cortex and that its synthesis and secretion are stimulated by adrenocorticotropic hormone (corticotropin [ACTH]). 12, [17] [18] [19] In humans 19 and animals, 18 ACTH-induced hypertension is associated with elevation of EO. Indeed, a preliminary report indicates that certain rare adrenocortical tumors, which are associated with severe hypertension, may produce prodigious amounts of EO. 20 Approximately 50% of humans with untreated essential hypertension and a majority of patients with adrenocortical adenomas and hypertension have significantly elevated plasma EO; moreover, BP correlates directly with plasma EO. 21 Even in normal human subjects, a high-NaCl diet elevates plasma EO, 22 and a 10-minute infusion of low-dose ouabain increases vascular resistance and elevates BP for Ͼ60 minutes. 23 Plasma EO levels are elevated in several rodent NaClsensitive hypertension models, 12, 24, 25 and chronic administration of low-dose ouabain to normal rodents usually induces hypertension in 1 to 3 weeks. 26, 27 Furthermore, subpressor doses of ouabain and DOCA act synergistically to induce hypertension. 28 Ouabain-induced BP elevation in rodents is counteracted by the ouabain antagonist PST-2238 (rostafuroxin). 29 Also, in ACTH, 18, 30 DOCAϩNaCl, 31 or reduced renal mass 25 hypertension, Digibind (digoxin-selective Fab fragments that bind ouabain with high affinity) 32 lowers BP.
Interestingly, low-dose ouabain increases TPR in dogs but does not raise BP, presumably because heart rate and CO are markedly reduced. 33 Ouabain also does not induce hypertension in sheep 34 or in mineralocorticoid-resistant 35 LongEvans rats. 36 These apparent exceptions may, however, yield novel information to help clarify the relationship between EO and hypertension.
Many of the findings cited above provide strong evidence that circulating EO has a key role in the pathogenesis of NaClsensitive hypertension. Other studies suggest, however, that brain, not plasma, EO, 16 or even marinobufagenin, 37 may be important.
Surprisingly, digoxin, another cardiotonic steroid and Na,KATPase inhibitor, does not induce hypertension in rodents. 26, 38 Also, Digitalis glycosides do not elevate BP in patients treated for congestive heart failure or cardiac arrhythmias. 39 Remarkably, digoxin actually lowers BP in ouabain-hypertensive rats 26, 38 and in many patients with essential hypertension. 40 Thus, Strophanthus glycosides, such as ouabain, may interact differently with Na ϩ pumps than do the structurally distinct Digitalis glycosides. Moreover, many observations now indicate that EO is a growth hormone and that it may participate in a variety of kinase-mediated and other signaling pathways independent of its effects on Na ϩ pump-mediated Na ϩ transport. 41 43 ␤ is essential for pump function; it stabilizes the ␣ subunit conformation and chaperones the ␣␤ complex to the PM. 43, 44 In some tissues, a third subunit, ␥, may help to regulate Na ϩ pump activity. 44 There are 4 mammalian ␣ subunit isoforms (␣1 to ␣4); they are products of different genes but have Ϸ90% sequence identity, different expression patterns, 45 and different kinetics, 46 and they are differently regulated. 43, 47 All of the cells express Na ϩ pumps with an ␣1 subunit and Na ϩ pumps with another ␣ isoform. 43, 45 Skeletal, cardiac, and SMs, eg, express Na ϩ pumps with an ␣2 subunit, as well as pumps with an ␣1; most neurons express ␣1 and ␣3. 48 Renal epithelia express predominantly (Ͼ90% to 95%) Na ϩ pumps with ␣1, which mediate the final step in net transepithelial Na ϩ reabsorption. 47 The functions of the different ␣ subunit isoforms were elucidated by the discovery that, in a variety of cell types, Na ϩ pumps with an ␣2 or ␣3 subunit are confined to PM microdomains situated adjacent to "junctional" sarcoplasmic/ endoplasmic reticulum (jS/ER; Figure 1 ). 45 Here, these Na ϩ pumps colocalize with NCX, which are confined to the same PM microdomains. 45 Na ϩ pumps with an ␣1 subunit are more widely distributed in the PM but are apparently excluded from these microdomains. 49 Importantly, the PM microdomains are separated by only 12 to 20 nm from the jS/ER, 50 and these structures form a functional unit, termed the "PLasmERosome." 51 The volume of cytosol in the junctional space between the PM and jS/ER of a single PLasmERosome is only on the order of 10 Ϫ19 to 10 Ϫ18 L, 51 and diffusion of Na ϩ and Ca 2ϩ between this space and bulk cytosol is restricted. Thus, standing Na ϩ and Ca 2ϩ concentration gradients between these compartments and bulk cytosol can be maintained. [52] [53] [54] Differences in Na ϩ pump ␣ subunit isoform kinetics play a critical role in PLasmERosome function. The rodent ␣1 isoform has unusually low affinity for ouabain (K Ouabain Ͼ100 mol/L versus Ͻ0.05 mol/L in humans) 55 so that nanomolar ouabain inhibits only the ␣2 Na ϩ pumps in rodent arterial myocyte PLasmERosomes. 7 Even in humans, however, where ␣1 Na ϩ pumps have high affinity for ouabain, partial inhibition of Na ϩ pumps by nanomolar ouabain will raise [Na ϩ ] in the junctional space much more than in bulk cytosol. The reason is that the affinity of ␣2 Na ϩ pumps for Na ϩ is much lower (K Na Ϸ 22 mmol/L) than is the affinity of ␣1 Na ϩ pumps (K Na Ϸ 12 mmol/L). 46 The widespread distribution of ␣1 Na ϩ pumps implies that they have a "housekeeping" function: they control, primarily, [ signaling in the cells as well. 51 Modulation of ␣2 Na ϩ pumps in arterial myocyte PLasmERosomes by EO can, therefore, influence arterial tone and BP. Below, we have summarized recent studies in which genetic engineering and pharmacological manipulation of mouse Na ϩ pumps and NCX ( Figure  2 ) have been used to examine the roles of these transporters in the long-term control of BP.
Downstream Effector Mechanisms
␣2 Na ؉ Pumps
As already noted, chronic administration of exogenous ouabain induces hypertension in rodents. The questions we now address are: how does ouabain (or EO) elevate BP, and is it because of inhibition of SM ␣2 Na ϩ pumps, as implied above? If circulating ouabain (or EO) elevates BP by inhibiting arterial myocyte ␣2 Na ϩ pumps, reduced expression of ␣2 Na ϩ pumps should have a similar effect. Therefore, we studied mice with a null mutation in either the ␣1 or ␣2 Na ϩ pump. 56 Heterozygous (␣1 ϩ/Ϫ and ␣2 ϩ/Ϫ or ␣2 S/Ϫ ; see Figure 2 ), but not homozygous, null mutants survive, and they express Ϸ50% of the normal complement of ␣1 or ␣2 pump protein, respectively, in ASM. 7 Isolated mesenteric small arteries from the ␣2 ϩ/Ϫ but not ␣1 ϩ/Ϫ mice exhibit augmented myogenic reactivity in response to stepwise increases in intraluminal pressure and significantly elevated MT when pressurized to 70 mm Hg. 7 Nanomolar ouabain also augments myogenic reactivity and increases MT with an EC 50 of Ϸ1.3 nmol/L. 7 Consistent with these effects in isolated arteries, ␣2 ϩ/Ϫ but not ␣1 ϩ/Ϫ mice have significantly elevated BP (Figure 3 ). 7 Moreover, the ␣2 ϩ/Ϫ mice are "NaCl sensitive": a high-NaCl diet increases BP much more in these mice than in their wild-type (WT) littermates (Figure 3) .
The ␣2 ϩ/Ϫ mice are "global" single-allele null mutants, but it is important to determine whether the effects are the result of reduced ␣2 Na ϩ pump activity/expression in ASM. Recently, we found that expression of a short N-terminal segment of the ␣2 Na ϩ pump is dominant negative for expression of full-length ␣2 pumps. 57 Therefore, we generated dominant-negative mice (␣2 SM/DN ) that express the ␣2 N-terminal segment with an SM-specific myosin heavy chain promoter. 58 These mice exhibit greatly reduced ␣2 Na ϩ pump expression in artery SM ( Figure S4 , available in the online data supplement at http://hyper.ahajournals.org) and elevated BP (Figure 3) .
In a complimentary approach, ␣1 and ␣2 Na ϩ pumps were overexpressed, independently, in mice, under the control of an ␣-actin SM-specific promoter. 59 The mice that overexpressed ␣2, but not those that overexpressed ␣1, Na ϩ pumps had, on average, significantly reduced BP compared with WT mice (Figure 3) .
The roles of ouabain/EO and ␣2 Na ϩ pumps in elevating BP were also examined in 2 other ways. One type of study used rostafuroxin, a derivative of digitoxigenin, 60 that antagonizes the inhibitory action of ouabain on Na,K-ATPase. 29 In isolated arteries, rostafuroxin counteracted the augmentation of MT by nanomolar ouabain but not the (ouabain-independent) augmenting effect of reduced ␣2 expression on MT. 7 Rostafuroxin also lowered BP in ouabain-induced hypertension 29 and in Ϸ30% of humans with essential hypertension. 29 As an alternative, in a knockin study, 2 amino acids in the ␣2 Na ϩ pump ouabain-binding site were mutated to reduce, markedly, the affinity of the ␣2 pump for ouabain. 18, 48 Mice that expressed ouabain-resistant ␣2 pumps (␣2 R/R ) were resistant to ACTH-induced hypertension (Figure 4 ), 18 as well as to ouabain-induced hypertension. 48 Moreover, Digibind prevented the ouabain-induced elevation of BP in the WT mice ( Figure 4) . 48 Clearly, ACTH-induced hypertension depends on the existence of a high-affinity cardiotonic steroid binding site on the ␣2 Na ϩ pump and on a water-soluble ligand that binds to this site. The plasma level of this ligand (presumably EO) was increased by ACTH and, like ouabain, 32 bound to Digibind with high affinity. 48 These genetic engineering studies reveal that arterial myocyte ␣2 Na ϩ pumps mediate the effects of EO and play a role in the long-term regulation of BP. Genetically or pharmacologically reduced ␣2 activity elevates BP, whereas increased ␣2 activity lowers BP (Figures 2 and 3) . The next question is: by what specific mechanism does the altered ␣2 Na ϩ pump activity influence BP? The answer appears to lie in Na/Ca exchange. Figure 4 . Effects of ACTH on BP in mice with high (normal) and low ouabain affinity ␣2 Na ϩ pumps. ACTH (500 g/kg SC every 8 hoursϫ5 days) elevated BP in WT mice but not in mutant mice expressing ␣2 Na ϩ pumps with low affinity for ouabain (␣2 R/R ). 18 Treatment with Digibind (30 g/kg daily, 2 hours before BP measurement), which binds ouabain with high affinity, 32 but not control IgG␥, prevented the ACTH-induced elevation of BP in WT mice. **PϽ0.1 for the pairings indicated. These regraphed BP data were obtained by tail cuff, 18 and those that do not. 61 The predominant exchanger in arterial myocytes is K ϩ -independent NCX, although NCX that cotransports K ϩ with Ca 2ϩ has also been detected, 62 There are 3 mammalian NCX isoforms (NCX1 to NCX3), each the product of a different gene. 63 NCX1, which is expressed in ASM, has multiple splice variants; NCX1.3 is the main variant in arterial myocytes. 64 Inhibition of Na ϩ pumps by nanomolar ouabain augments Ca 2ϩ signaling without elevating bulk cytosolic Na ϩ in primary cultured rat arterial myocytes. 51 Even knockout of ␣2 Na ϩ pumps in cultured cells (astrocytes) has only a minimal effect on bulk cytosolic Na ϩ but a large effect on Ca 2ϩ signaling. 65 These findings are consistent with a functional linkage between ␣2 (but not ␣1) Na ϩ pumps and NCX1, and local reduction of the trans-PM Na ϩ gradient when ␣2 activity is reduced, as implied by the PLasmERosome model (Figure 1) . Moreover, recent pharmacological and genetic engineering studies now reveal that NCX1 influences not only arterial myocyte Ca 2ϩ metabolism but also long-term vascular tone and BP as well.
Mice in which NCX1 is overexpressed in SM with an ␣-actin promoter (NCX1 SM/Tg ) have elevated BP that is markedly increased by a high-NaCl diet; ie, the mice are NaCl sensitive (Figure 3) . 66 The elevated BP in the NCX1 overexpressors on high dietary NaCl is abolished by SEA0400, a selective NCX1 inhibitor, 67 but not if the overexpressed NCX1 contains a G833C mutation, 66 which specifically abrogates the action of SEA0400. 68 To perform the converse experiment, mice with floxed NCX1 (NCX1 flx/flx ) 69 were crossed with mice containing a Cre recombinase gene under the control of the SM myosin heavy chain promoter 58 to generate SM-specific NCX1 knockout (NCX1 SMϪ/Ϫ ) mice. NCX1 SMϪ/Ϫ mice have abnormally low BP (Figure 3) , and isolated, pressurized small arteries from these mice have abnormally low MT. 70 Indeed, SEA0400 also lowers BP by Ϸ5 to 10 mm Hg in WT mice 66 and reduces MT by Ϸ10% in isolated arteries from these mice. 7, 66 Thus, NCX1 activity apparently makes a modest but direct contribution to normal MT and BP. SEA0400 also attenuates the increased MT in arteries from ␣2 ϩ/Ϫ mice, 7 indicating that NCX1 mediates effects distal to ␣2 Na ϩ pumps. The BP and MT data from ␣2 ϩ/Ϫ and NCX1 SMϪ/Ϫ mice support the view that MT in isolated arteries is an in vitro reflection of BP 6 and, most likely, TPR. The mice with genetically engineered NCX1 demonstrate that this exchanger contributes to long-term BP regulation: increased NCX1 expression increases BP, whereas knockout of NCX1 reduces BP (Figures 2 and 3 ). This conclusion is supported by the effects of NCX blockers in several rodent models of NaCl-dependent or ACTH-induced hypertension. In DOCAϩNaCl hypertensive rats, spontaneously hypertensive rats on a high-NaCl diet, and Dahl NaCl-sensitive rats on high NaCl, SEA0400 markedly reduces BP. 66 Also, KB-R7943, a less potent NCX blocker, prevents ACTH from elevating BP in mice. 18 Moreover, although a null mutation in one NCX1 allele has a negligible effect on BP (NCX1 ϩ/Ϫ in Figure 3 ) or MT, 71 it prevents the induction of hypertension by DOCAϩNaCl. 66 Importantly, SEA0400 did not lower BP in several NaCl-independent rat hypertension models: spontaneously hypertensive rats on a normal NaCl diet, stroke-prone spontaneously hypertensive rats, and the renin-dependent 2-kidney/1-clip rat. 66 The implication is that NCX1 makes an important contribution to the pathogenesis of NaCl-dependent hypertension but not to NaCl-independent hypertension.
"Kalzium? Ja, Das ist Alles!" (Calcium Is Everything: O. Loewi)
Arterial myocyte contraction depends, ultimately, on the availability of cytosolic Ca 2ϩ , 8 and the sensitivity of the contractile apparatus to that Ca 2ϩ . 72 Furthermore, NCX1, under the control of the Na ϩ gradient generated by the adjacent ␣2 Na ϩ pumps, helps regulate myocyte Ca 2ϩ ho- 
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meostasis (Figure 1 ). For example, the nanomolar ouabaininduced increase in MT is associated with increased myocyte [Ca 2ϩ ] 7 ; conversely, reduction of MT by SEA0400 is associated with reduced myocyte [Ca 2ϩ ] ( Figure 5 ). 66 Thus, it is apparent that ␣2 Na ϩ pumps and NCX1 are relatively distal mechanisms in the final common path that links NaCl to vasoconstriction and hypertension (Figure 2) . Indeed, all upstream vasoconstrictor and vasodilator mechanisms (neural and humoral) must, inevitably, be influenced by the activity of these 2 transporters, because they regulate basal [Ca 2ϩ ] CYT in arterial myocytes.
An alternative suggestion is that activation of Rho/Rho kinase via the G 12 -G 13 -mediated G protein-coupled receptor pathway, which modulates the Ca 2ϩ sensitivity of the contractile apparatus in ASM, 72 is selective for NaCl-dependent hypertension. 73 Those authors, however, studied only an NaCl-dependent (DOCAϩNaCl) mouse model; they did not test whether the G 12 -G 13 pathway also operates in NaClindependent forms of hypertension. 73 In fact, interference with the G 12 -G 13 pathway, whether at the agonist receptor level 74 or at the level of the Rho kinase, 75 lowers BP in NaCl-independent models, such as the stroke-prone spontaneously hypertensive rat 74 and the NO synthase-inhibited rat. 75 The G 12 -G 13 pathway is, therefore, downstream and distinct from the key NaCl-sensitive steps in Na ϩ -dependent hypertension. Once NaCl-sensitive, NCX1-mediated Ca 2ϩ entry has occurred, the G 12 -G 13 pathway helps modulate the increases in vascular tone and BP.
Endgame: Na/Ca Exchange, Ca 2؉ Entry, and Myogenic Tone
In the heart, the main role of NCX is to extrude, during diastole, much of the Ca 2ϩ that enters through voltage-gated channels during systole. 76 Consequently, reduced cardiac NCX1 function as a result, eg, of ␣2 Na ϩ pump inhibition by cardiotonic steroids, is associated with Ca 2ϩ gain and augmented signaling in cardiac myocytes. Therefore, it might at first seem surprising that ASM NCX1 contributes directly to vascular tone and that reduced expression or pharmacological inhibition of NCX1 in arterial myocytes lowers [Ca 2ϩ ] CYT and attenuates Ca 2ϩ signaling ( Figure 5 ). Indeed, Ca 2ϩ entry via NCX has sometimes been called "reverse mode" exchange, implying, erroneously, that this is the backward or abnormal operation of the exchanger. 77 NCX can transport Ca 2ϩ in either direction across the PM, 78 under the control of the local Na ϩ electrochemical gradient across the PM ( Figure  1) , and considerations of the electric component of this gradient are of paramount importance. In the heart, the driving force on the exchanger, ie, the difference between the prevailing membrane voltage (V M ) and the NCX1 reversal potential (E Na/Ca ), which determines the direction of net Ca 2ϩ movement, varies during the cardiac cycle. {For NCX1, which mediates the exchange of 3Na ϩ for 1Ca 2ϩ , E Na/Ca ϭ 3E Na Ϫ2E Ca , where E Na and E Ca are, respectively, the equilibrium potentials for Na ϩ and Ca
2ϩ
.
, and R, T, and F are the gas constant, temperature in degrees Kelvin, and Faraday's number, respectively. 78 } The rapid membrane depolarization during the upstroke of the cardiac action potential, for example, rapidly switches NCX1 from the Ca 2ϩ exit to Ca 2ϩ entry mode, as the driving force, V M -E Na/Ca , becomes positive. Then, as V M repolarizes, during diastole, V M ϪE Na/Ca again becomes negative and favors Ca 2ϩ exit. 78 A different situation exists in ASM, where changes in V M are normally quite slow, and cells are often partially depolarized for very long periods of time. 79 Here, intraluminal pressure in small arteries depolarizes the myocytes and activates dihydropyridine-sensitive L-type voltage-gated channels. Opening of stretch-activated nonselective cation channels 80 may initiate the depolarization. This depolarization is insensitive to dihydropyridines: nifedipine blocks Ca 2ϩ entry through L-type voltage-gated channels and reduces MT but has little effect on the pressure-activated depolarization. 79 The Na ϩ entry through stretch-activated channels and consequent depolarization, as well as the rise in [Ca 2ϩ ] CYT , 80 should also have another, previously unrecognized consequence: they should promote Ca 2ϩ entry via NCX1 and thereby contribute to MT. The reason is that the exchanger is activated by cytosolic Ca 2ϩ , 81 and the rise in cytosolic [Na ϩ ] and the depolarization augment the Ca 2ϩ entry mode of NCX1 by increasing the driving force, V M ϪE Na/Ca . The implication is that both the L-type voltagegated channels and NCX1 contribute to the maintenance of Ca 2ϩ entry, elevated [Ca 2ϩ ] CYT , and arterial tone when the arteries are pressurized.
"In My End Is My Beginning" (T.S. Eliot)
In this review, we have explored some of the critical steps that link NaCl retention with the long-term increase in TPR and elevation of BP. Recent results, especially those from chemical analyses of human and rodent plasma samples and from genetic engineering and pharmacological studies in rodents and rodent arteries are summarized above. These studies give new insight into some of the molecular events that help regulate cytosolic Ca 2ϩ and vascular tone. The data supply compelling evidence that EO, SM ␣2 Na ϩ pumps, and NCX1 are key mechanisms in the pathway that leads from NaCl retention to hypertension (Figure 2) . These findings provide a framework, but the story is far from complete. For example, a key area where knowledge is lacking is at the early steps between NaCl retention and the release of EO, as indicated by the broken vertical lines in Figure 2 . Also, Crowley et al 82 demonstrated recently that the renal and extrarenal arteries make apparently independent (and equal) contributions to the long-term regulation of BP, but how the distal mechanisms, discussed above, affect the renal and extrarenal vasculature and renal function and thereby contribute to BP control is still unexplored. Finally, of course, a fundamental question is: what makes us NaCl sensitive in the first place? Hopefully, the progress outlined above will clarify new directions for hypertension research to help resolve these issues. 
Assay of Endogenous and Exogenous Ouabain.
Mass spectroscopy (MS) methods reveal that the endogenous ouabain (EO) isolated from human plasma has a mass of 584.2 daltons, identical to that obtained for plant-derived ouabain. 1 Advances in MS instrumentation, coupled with improved understanding of the behavior of various ion adducts of EO in the gas phase, now enable quantitation and fingerprinting of EO using small clinically relevant volumes of blood. 2 Examples of the liquid chromatographytandem MS-MS (LC-MS-MS) of endogenous ouabain from 0.25 ml rat plasma and plant derived ouabain are shown in Supplementary Figures 1 and 2 , respectively.
Inspection of the key ion current chromatograms and the MS-MS spectra prove the presence of EO in normal rat plasma and show (in this instance) that it circulates at the high end of the subnanomolar range as documented by prior RIA and bioassay methods. Immunoblots of aorta and bladder smooth muscle, and brain, membranes from wild type (C) and smooth muscle-specific α2 dominant negative (α2 SM/DN ) mice (DN). An α2(1-120)Flag construct, the Nterminal 120 amino acid residues of the α2 Na + pump, under the control of a smooth muscle myosin heavy chain promoter, was expressed in the α2 SM/DN mice.
The construct expression was detected with anti-Flag antibodies in smooth muscle (bladder; insufficient aorta protein was available), but not in brain. The Na + pump α2 subunit (detected with anti-α2 HERED antibodies) was downregulated in both smooth muscles, but not in brain. Lane protein content was controlled with α-actin (Song, Chen, Kotlikoff and Blaustein, unpublished).
